+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030- Product Image
Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030- Product Image
Sale

Biosimilars Market by Product Type, Therapeutic Area, Administration Route, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083156
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The biosimilars market is evolving rapidly, propelled by regulatory advancements, technological innovation, and shifting healthcare economics. Senior decision-makers are navigating a landscape defined by intensifying competition, complex reimbursement frameworks, and the need for strategic adaptability. Understanding nuanced market dynamics is essential for sustaining leadership and identifying new avenues for growth in this transformative environment.

Market Snapshot: Biosimilars Market Trends and Growth

The Biosimilars Market expanded from USD 49.91 billion in 2024 to USD 61.84 billion in 2025. The sector is forecast to maintain robust momentum with a CAGR of 23.47%, positioning it to reach USD 176.90 billion by 2030. This growth is attributed to increased adoption of biosimilars as cost-effective alternatives to originator products, particularly as stakeholders across the globe respond to cost pressures and regulatory facilitation. As market competition intensifies, both established manufacturers and emerging players are focusing on innovation, development efficiency, and broader market access.

Scope & Segmentation

This report delivers a comprehensive view of the biosimilars market by examining essential segmentation and regional nuances.

  • Product Types: Erythropoietins (Darbepoetin Alfa, Epoetin Alfa), Granulocyte Colony Stimulating Factors (Filgrastim, Pegfilgrastim), Growth Hormones (Somatropin), Insulins (Human Insulin – NPH, Regular; Insulin Analogs – Long Acting, Rapid Acting), Interferons (Alpha, Beta, Gamma), Monoclonal Antibodies (Anti-TNF agents such as Adalimumab, Infliximab biosimilars; Non-TNF agents: Bevacizumab, Rituximab, Trastuzumab biosimilars)
  • Therapeutic Areas: Endocrinology, Hematology, Immunology, Infectious Diseases, Oncology
  • Administration Routes: Intramuscular, Intravenous, Subcutaneous
  • End Users: Clinics, Homecare, Hospitals
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notably United Kingdom, Germany, France, and other markets), Asia-Pacific (including China, India, Japan, Australia, South Korea, and Southeast Asian countries)
  • Key Companies: Sandoz International GmbH, Pfizer Inc., Amgen Inc., Samsung Bioepis Co., Ltd., Celltrion Inc., Biocon Limited, Viatris Inc., Merck KGaA, Fresenius Kabi AG, Coherus BioSciences Inc.

Key Takeaways for Decision-Makers

  • Regulatory harmonization is streamlining approval processes, supporting faster market entry and stimulating competition among biosimilars manufacturers.
  • Technological advances, such as process automation, cloud-based analytics, and artificial intelligence, are enabling reduced production costs and improved batch consistency.
  • Payers are shifting toward value-based care models, driving greater emphasis on real-world outcomes and evidence to inform formulary inclusion.
  • Manufacturers are proactively expanding supply chain diversification and investing in local production capabilities to address shifting trade landscapes and improve market resilience.
  • End-user segmentation underscores the need for tailored strategies as procurement priorities differ for clinics, homecare, and hospitals.
  • Strategic partnerships and innovation in product portfolios, including next-generation biologics, are supporting differentiation in a maturing global competitive environment.

Tariff Impact on the Biosimilars Ecosystem

Forthcoming US tariffs on imported biologics and related components in 2025 are set to reshape cost structures and influence sourcing strategies throughout the biosimilars ecosystem. While designed to bolster domestic manufacturing, these measures may drive manufacturers to seek alternative supply chains, pursue onshore partnerships, and negotiate new contract terms with payers responding to shifting landed costs. Overall, navigating this evolving trade policy environment will require adaptability in procurement and pricing strategies.

Market Research Methodology & Data Sources

This analysis combines comprehensive secondary research—including peer-reviewed publications, regulatory filings, and industry presentations—with structured interviews of executives, key opinion leaders, and procurement experts. Segmentation and qualitative findings are validated through triangulation and thorough expert review, ensuring credibility and actionable depth for industry leaders.

Biosimilars Market: Why This Report Matters

  • Delivers actionable segmentation and benchmarking to identify new growth channels and mitigate competitive risks.
  • Equips decision-makers with clarity on the impact of regulatory shifts and trade policies on operational efficiency and market access.
  • Supports informed, data-driven planning for supply network strategies, portfolio expansion, and payer engagement initiatives.

Conclusion

Strategic foresight and agile execution are critical for navigating the dynamic biosimilars market. This report offers a roadmap for optimizing market positioning and responding to technological, regulatory, and commercial shifts. By leveraging these insights, stakeholders can advance sustainable growth and value creation across the biosimilars landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biosimilars Market, by Product Type
8.1. Introduction
8.2. Erythropoietins
8.2.1. Darbepoetin Alfa
8.2.2. Epoetin Alfa
8.3. Granulocyte Colony Stimulating Factors
8.3.1. Filgrastim
8.3.2. Pegfilgrastim
8.4. Growth Hormones
8.4.1. Somatropin
8.5. Insulins
8.5.1. Human Insulin
8.5.1.1. NPH Insulin
8.5.1.2. Regular Insulin
8.5.2. Insulin Analogs
8.5.2.1. Long Acting Analog
8.5.2.2. Rapid Acting Analog
8.6. Interferons
8.6.1. Interferon Alpha
8.6.2. Interferon Beta
8.6.3. Interferon Gamma
8.7. Monoclonal Antibodies
8.7.1. Anti-Tnf Agents
8.7.1.1. Adalimumab Biosimilars
8.7.1.2. Infliximab Biosimilars
8.7.2. Non-Tnf Agents
8.7.2.1. Bevacizumab Biosimilars
8.7.2.2. Rituximab Biosimilars
8.7.2.3. Trastuzumab Biosimilars
9. Biosimilars Market, by Therapeutic Area
9.1. Introduction
9.2. Endocrinology
9.3. Hematology
9.4. Immunology
9.5. Infectious Diseases
9.6. Oncology
10. Biosimilars Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Subcutaneous
11. Biosimilars Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
12. Americas Biosimilars Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Biosimilars Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Biosimilars Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Sandoz International GmbH
15.3.2. Pfizer Inc.
15.3.3. Amgen Inc.
15.3.4. Samsung Bioepis Co., Ltd.
15.3.5. Celltrion, Inc.
15.3.6. Biocon Limited
15.3.7. Viatris Inc.
15.3.8. Merck KGaA
15.3.9. Fresenius Kabi AG
15.3.10. Coherus BioSciences, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BIOSIMILARS MARKET MULTI-CURRENCY
FIGURE 2. BIOSIMILARS MARKET MULTI-LANGUAGE
FIGURE 3. BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY SOMATROPIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY NPH INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY LONG ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON ALPHA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON BETA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON GAMMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY BEVACIZUMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOSIMILARS MARKET SIZE, BY TRASTUZUMAB BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOSIMILARS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOSIMILARS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOSIMILARS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOSIMILARS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOSIMILARS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOSIMILARS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOSIMILARS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOSIMILARS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 90. CANADA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 91. CANADA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 92. CANADA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 96. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 97. CANADA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 98. CANADA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 99. CANADA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 100. CANADA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 175. GERMANY BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 177. GERMANY BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 179. GERMANY BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 181. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 185. GERMANY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 188. FRANCE BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 189. FRANCE BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 191. FRANCE BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 192. FRANCE BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 193. FRANCE BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 195. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. FRANCE BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 198. FRANCE BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 199. FRANCE BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 200. FRANCE BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. ITALY BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 217. ITALY BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 218. ITALY BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 219. ITALY BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 220. ITALY BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 221. ITALY BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 222. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 223. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 224. ITALY BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 225. ITALY BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 226. ITALY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 227. ITALY BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 228. ITALY BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. SPAIN BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 231. SPAIN BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 232. SPAIN BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 233. SPAIN BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 234. SPAIN BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 235. SPAIN BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 236. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 237. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. SPAIN BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 239. SPAIN BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 240. SPAIN BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 241. SPAIN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 242. SPAIN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 270. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 286. DENMARK BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 287. DENMARK BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 288. DENMARK BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 289. DENMARK BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 290. DENMARK BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 291. DENMARK BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 292. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 293. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. DENMARK BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 295. DENMARK BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 296. DENMARK BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 297. DENMARK BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 298. DENMARK BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 311. NETHERLANDS BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 312. NETHERLANDS BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. QATAR BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 315. QATAR BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 316. QATAR BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 317. QATAR BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 318. QATAR BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 319. QATAR BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 320. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 321. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 322. QATAR BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 323. QATAR BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 324. QATAR BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 325. QATAR BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 326. QATAR BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. FINLAND BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 329. FINLAND BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 330. FINLAND BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 331. FINLAND BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 332. FINLAND BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 333. FINLAND BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 334. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 335. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 336. FINLAND BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 337. FINLAND BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 338. FINLAND BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 339. FINLAND BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 340. FINLAND BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 341. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 342. SWEDEN BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 343. SWEDEN BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 344. SWEDEN BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 345. SWEDEN BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 346. SWEDEN BIOSIMILARS MARKET SIZE, BY HUMAN INSULIN, 2018-2030 (USD MILLION)
TABLE 347. SWEDEN BIOSIMILARS MARKET SIZE, BY INSULIN ANALOGS, 2018-2030 (USD MILLION)
TABLE 348. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
TABLE 349. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 350. SWEDEN BIOSIMILARS MARKET SIZE, BY ANTI-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 351. SWEDEN BIOSIMILARS MARKET SIZE, BY NON-TNF AGENTS, 2018-2030 (USD MILLION)
TABLE 352. SWEDEN BIOSIMILARS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 353. SWEDEN BIOSIMILARS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 354. SWEDEN BIOSIMILARS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 355. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. NIGERIA BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETINS, 2018-2030 (USD MILLION)
TABLE 357. NIGERIA BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY STIMULATING FACTORS, 2018-2030 (USD MILLION)
TABLE 358. NIGERIA BIOSIMILARS MARKET SIZE, BY GROWTH HORMONES, 2018-2030 (USD MILLION)
TABLE 359. NIGERIA BIOSIMILARS MARKET SIZE, BY INSULINS, 2018-2030 (USD MILLION)
TABLE 360. NIGERIA BIOSIMILARS MARKET

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Biosimilars market report include:
  • Sandoz International GmbH
  • Pfizer Inc.
  • Amgen Inc.
  • Samsung Bioepis Co., Ltd.
  • Celltrion, Inc.
  • Biocon Limited
  • Viatris Inc.
  • Merck KGaA
  • Fresenius Kabi AG
  • Coherus BioSciences, Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 61.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 176.9 Billion
Compound Annual Growth Rate23.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035 - Product Image

Biosimilars Market by Drug Class (mAbs (Adalimumab, Infliximab, Rituximab, Trastuzumab), GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2035

  • Report
  • 392 Pages
  • Global
From
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Biosimilars Market - Products, Applications and Regulations - Product Image

Biosimilars Market - Products, Applications and Regulations

  • Report
  • 227 Pages
  • Global
From
Biosimilars Market Report 2025 - Product Image

Biosimilars Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.